Benzinga's Top Upgrades, Downgrades For August 25, 2020

Upgrades

• According to Telsey Advisory Group, the prior rating for Burlington Stores Inc BURL was changed from Market Perform to Outperform. In the first quarter, Burlington Stores showed an EPS of $4.76, compared to $1.26 from the year-ago quarter. At the moment, the stock has a 52-week-high of $250.89 and a 52-week-low of $105.67. Burlington Stores closed at $194.23 at the end of the last trading period.
• According to Citigroup, the prior rating for Gap Inc GPS was changed from Neutral to Buy. For the first quarter, Gap had an EPS of $2.51, compared to year-ago quarter EPS of $0.24. The current stock performance of Gap shows a 52-week-high of $19.86 and a 52-week-low of $5.26. Moreover, at the end of the last trading period, the closing price was at $15.51.
• For L Brands Inc LB, MKM Partners upgraded the previous rating of Neutral to the current rating Buy. For the second quarter, L Brands had an EPS of $0.25, compared to year-ago quarter EPS of $0.24. The current stock performance of L Brands shows a 52-week-high of $31.33 and a 52-week-low of $8.00. Moreover, at the end of the last trading period, the closing price was at $29.63.
• According to UBS, the prior rating for NIO Inc NIO was changed from Sell to Neutral. NIO earned $0.15 in the second quarter, compared to $0.45 in the year-ago quarter. At the moment, the stock has a 52-week-high of $16.44 and a 52-week-low of $1.19. NIO closed at $14.97 at the end of the last trading period.
• For Starbucks Corp SBUX, Stifel upgraded the previous rating of Hold to the current rating Buy. For the third quarter, Starbucks had an EPS of $0.46, compared to year-ago quarter EPS of $0.78. The stock has a 52-week-high of $98.14 and a 52-week-low of $50.02. At the end of the last trading period, Starbucks closed at $78.68.
• For Crocs Inc CROX, B. Riley FBR upgraded the previous rating of Neutral to the current rating Buy. In the second quarter, Crocs showed an EPS of $1.01, compared to $0.59 from the year-ago quarter. The current stock performance of Crocs shows a 52-week-high of $43.79 and a 52-week-low of $8.40. Moreover, at the end of the last trading period, the closing price was at $39.34.
• According to CIBC, the prior rating for Mercer International Inc MERC was changed from Neutral to Outperformer. Mercer International earned $0.13 in the second quarter, compared to $0.16 in the year-ago quarter. The stock has a 52-week-high of $13.62 and a 52-week-low of $6.42. At the end of the last trading period, Mercer International closed at $8.00.

Downgrades

• For Portland General Electric Co POR, B of A Securities downgraded the previous rating of Buy to the current rating Neutral. Portland General Electric earned $0.43 in the second quarter, compared to $0.28 in the year-ago quarter. The stock has a 52-week-high of $63.08 and a 52-week-low of $37.83. At the end of the last trading period, Portland General Electric closed at $41.96.
• Jefferies downgraded the previous rating for Galapagos NV GLPG from Buy to Hold. In the second quarter, Galapagos showed an EPS of $1.95, compared to $0.96 from the year-ago quarter. The stock has a 52-week-high of $274.03 and a 52-week-low of $112.00. At the end of the last trading period, Galapagos closed at $134.83.
• According to Atlantic Equities, the prior rating for Nutrien Ltd NTR was changed from Overweight to Neutral. For the second quarter, Nutrien had an EPS of $1.45, compared to year-ago quarter EPS of $1.58. The current stock performance of Nutrien shows a 52-week-high of $52.41 and a 52-week-low of $23.85. Moreover, at the end of the last trading period, the closing price was at $39.06.
• Stifel downgraded the previous rating for Old Dominion Freight Line Inc ODFL from Hold to Sell. Old Dominion Freight Line earned $1.25 in the second quarter, compared to $2.16 in the year-ago quarter. At the moment, the stock has a 52-week-high of $227.21 and a 52-week-low of $119.01. Old Dominion Freight Line closed at $198.83 at the end of the last trading period.
• For Momenta Pharmaceuticals Inc MNTA, HC Wainwright & Co. downgraded the previous rating of Buy to the current rating Neutral. In the second quarter, Momenta Pharmaceuticals showed an EPS of $0.48, compared to $1.16 from the year-ago quarter. The current stock performance of Momenta Pharmaceuticals shows a 52-week-high of $52.32 and a 52-week-low of $11.91. Moreover, at the end of the last trading period, the closing price was at $52.15.

Initiations

• Aegis Capital initiated coverage on MICT Inc MICT with a Buy rating. The price target for MICT is set to $6.00. In the second quarter, MICT showed an EPS of $0.00, compared to $0.10 from the year-ago quarter. At the moment, the stock has a 52-week-high of $8.45 and a 52-week-low of $0.38. MICT closed at $3.59 at the end of the last trading period.
• Truist Securities initiated coverage on Forte Biosciences Inc FBRX with a Buy rating. The price target for Forte Biosciences is set to $70.00. The stock has a 52-week-high of $25.49 and a 52-week-low of $17.90. At the end of the last trading period, Forte Biosciences closed at $24.70.
• With a current rating of Overweight, Wells Fargo initiated coverage on NXP Semiconductors NV NXPI. The price target seems to have been set at $145.00 for NXP Semiconductors. In the second quarter, NXP Semiconductors showed an EPS of $0.91, compared to $1.91 from the year-ago quarter. The current stock performance of NXP Semiconductors shows a 52-week-high of $139.59 and a 52-week-low of $58.41. Moreover, at the end of the last trading period, the closing price was at $123.78.
• Ladenburg Thalmann initiated coverage on Synchronoss Technologies Inc SNCR with a Buy rating. The price target for Synchronoss Technologies is set to $8.00. In the second quarter, Synchronoss Technologies showed an EPS of $0.16, compared to $0.28 from the year-ago quarter. The current stock performance of Synchronoss Technologies shows a 52-week-high of $8.78 and a 52-week-low of $2.17. Moreover, at the end of the last trading period, the closing price was at $4.39.
• With a current rating of Buy, B of A Securities initiated coverage on Vasta Platform Ltd VSTA. The price target seems to have been set at $21.50 for Vasta Platform. Vasta Platform earned $0.12 in the second quarter. At the moment, the stock has a 52-week-high of $19.43 and a 52-week-low of $15.31. Vasta Platform closed at $16.02 at the end of the last trading period.
• Stifel initiated coverage on Vital Farms Inc VITL with a Buy rating. The price target for Vital Farms is set to $43.00. The stock has a 52-week-high of $43.30 and a 52-week-low of $34.51. At the end of the last trading period, Vital Farms closed at $39.38.
• With a current rating of Outperform, Raymond James initiated coverage on ACADIA Pharmaceuticals Inc ACAD. The price target seems to have been set at $65.00 for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals earned $0.27 in the second quarter, compared to $0.38 in the year-ago quarter. The stock has a 52-week-high of $58.72 and a 52-week-low of $23.77. At the end of the last trading period, ACADIA Pharmaceuticals closed at $38.00.
• Raymond James initiated coverage on argenx SE ARGX with an Outperform rating. The price target for argenx is set to $257.00. For the second quarter, argenx had an EPS of $3.15, compared to year-ago quarter EPS of $1.12. The current stock performance of argenx shows a 52-week-high of $272.74 and a 52-week-low of $103.75. Moreover, at the end of the last trading period, the closing price was at $232.77.
• 86 Research initiated coverage on Baozun Inc BZUN with a Hold rating. The price target for Baozun is set to $43.00. In the second quarter, Baozun showed an EPS of $0.34, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $50.33 and a 52-week-low of $22.19. At the end of the last trading period, Baozun closed at $40.99.
• Raymond James initiated coverage on Global Blood Therapeutics Inc GBT with an Outperform rating. The price target for Global Blood Therapeutics is set to $115.00. For the second quarter, Global Blood Therapeutics had an EPS of $0.86, compared to year-ago quarter EPS of $1.01. The current stock performance of Global Blood Therapeutics shows a 52-week-high of $87.54 and a 52-week-low of $39.95. Moreover, at the end of the last trading period, the closing price was at $62.61.
• For GW Pharmaceuticals PLC GWPH, Raymond James initiated coverage, by setting the current rating at Market Perform. GW Pharmaceuticals earned $0.02 in the third quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of $151.35 and a 52-week-low of $67.98. At the end of the last trading period, GW Pharmaceuticals closed at $106.27.
• Raymond James initiated coverage on Immunovant Inc IMVT with an Outperform rating. The price target for Immunovant is set to $35.00. Immunovant earned $0.38 in the fourth quarter. The stock has a 52-week-high of $35.50 and a 52-week-low of $8.34. At the end of the last trading period, Immunovant closed at $33.48.
• With a current rating of Buy, Deutsche Bank initiated coverage on Jack In The Box Inc JACK. The price target seems to have been set at $100.00 for Jack In The Box. In the third quarter, Jack In The Box showed an EPS of $1.37, compared to $1.07 from the year-ago quarter. The stock has a 52-week-high of $93.12 and a 52-week-low of $16.81. At the end of the last trading period, Jack In The Box closed at $83.36.
• Raymond James initiated coverage on PTC Therapeutics Inc PTCT with an Outperform rating. The price target for PTC Therapeutics is set to $63.00. For the second quarter, PTC Therapeutics had an EPS of $2.62, compared to year-ago quarter EPS of $0.75. The stock has a 52-week-high of $59.89 and a 52-week-low of $30.79. At the end of the last trading period, PTC Therapeutics closed at $48.04.
• Raymond James initiated coverage on uniQure NV QURE with a Strong Buy rating. The price target for uniQure is set to $75.00. For the second quarter, uniQure had an EPS of $0.96, compared to year-ago quarter EPS of $0.83. At the moment, the stock has a 52-week-high of $76.69 and a 52-week-low of $36.20. uniQure closed at $38.21 at the end of the last trading period.
• Raymond James initiated coverage on Sarepta Therapeutics Inc SRPT with an Outperform rating. The price target for Sarepta Therapeutics is set to $200.00. Sarepta Therapeutics earned $1.51 in the second quarter, compared to $0.83 in the year-ago quarter. The stock has a 52-week-high of $175.00 and a 52-week-low of $72.05. At the end of the last trading period, Sarepta Therapeutics closed at $141.20.
• Morgan Stanley initiated coverage on Vasta Platform Ltd VSTA with an Overweight rating. The price target for Vasta Platform is set to $20.00. Vasta Platform earned $0.12 in the second quarter. At the moment, the stock has a 52-week-high of $19.43 and a 52-week-low of $15.31. Vasta Platform closed at $16.02 at the end of the last trading period.
• For Zogenix Inc ZGNX, Raymond James initiated coverage, by setting the current rating at Market Perform. In the second quarter, Zogenix showed an EPS of $0.96, compared to $0.89 from the year-ago quarter. The stock has a 52-week-high of $57.22 and a 52-week-low of $16.65. At the end of the last trading period, Zogenix closed at $22.93.
• With a current rating of Buy, HC Wainwright & Co. initiated coverage on Kopin Corp KOPN. The price target seems to have been set at $2.00 for Kopin. Kopin earned $0.01 in the second quarter, compared to $0.05 in the year-ago quarter. The current stock performance of Kopin shows a 52-week-high of $2.16 and a 52-week-low of $0.19. Moreover, at the end of the last trading period, the closing price was at $1.37.
• Jefferies initiated coverage on Vital Farms Inc VITL with a Buy rating. The price target for Vital Farms is set to $47.00. The stock has a 52-week-high of $43.30 and a 52-week-low of $34.51. At the end of the last trading period, Vital Farms closed at $39.38.